Loblaw Co (L.TO):

Written by

Revenue of C$19,395 million, up 4.6% versus the prior year period. Loblaw
- Excluding the impact of the sale of the Wellwise business (which contributed ~C$27 million in the prior year), the revenue growth was about 4.8%. Loblaw
- Retail segment sales (food + drug retail) were C$19,082 million, up ~4.5%. Loblaw
  - Food Retail: C$13,588 million, up ~4.8%. Same-store sales +2.0%. Loblaw
  - Drug Retail: C$5,494 million, up ~3.8%. Same-store sales +4.0% (front-store +1.9%; pharmacy & healthcare services +5.9%). Loblaw
- E-commerce sales rose by 18.0%. Loblaw
Operating income: C$1,376 million (increase of ~$55 million or ~4.2%). Loblaw
Adjusted EBITDA: C$2,217 million, up 7.2%. Loblaw
Net earnings available to common shareholders: C$794 million, up C$17 million or ~2.2%. Loblaw
Diluted net earnings per share (EPS): C$0.66, up ~4.8% year-over-year. Loblaw
Adjusted diluted EPS: C$0.69, up ~11.3%. Loblaw
Capital expenditures (net of disposals): C$682 million; gross capex C$685 million. Loblaw
Share-buyback: 6.8 million common shares repurchased/cancelled at cost C$381 million in the quarter. Loblaw

Comments